MN-CARGILL
1.2.2024 07:04:08 CET | Business Wire | Press release
As of Jan. 1, 2024, every Cargill food customer, no matter where they are in the world, can be confident that the company’s fats and oils comply with the World Health Organization’s (WHO) recommended maximum tolerance level for industrially produced trans-fatty acids (iTFA) in fats and oils. Cargill has achieved this milestone by becoming the first global supplier whose entire worldwide edible oils portfolio meets the WHO’s best practice standard on iTFAs, limiting iTFA content to no more than two grams per 100 grams of fats/oils, including in countries where there is currently no legislative mandate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131485973/en/
Cargill has helped hundreds of customers reformulate and innovate nutritious and tasty products that meet WHO standards on iTFA (Photo: Business Wire)
While Cargill announced its commitment to removing iTFAs from its fats and oils portfolio in December 2021, the achievement reflects decades of work. The company’s iTFA journey spans more than a quarter century including early innovation, millions of dollars of investments in capital expenses and resources, and thousands of R&D hours. Along the way, Cargill has helped more than 400 customers create nutritious and tasty products that contribute to happier, healthier lives, removing more than 1.5 billion pounds of products containing iTFAs from the global food supply.
“We’re pleased to see Cargill’s continued commitment to reduce industrially produced trans fats in all their oils, recently achieving their goal to align with the World Health Organization’s recommended standards,” says René Lammers, PepsiCo’s chief science officer. “This move aligns with PepsiCo’s successful reduction of iTFAs in our foods to meet this same standard, and we encourage our fellow industry partners to join us in this important initiative to evolve our food and beverage portfolio to be better for the planet and people.”
In the past two years alone, Cargill has invested an additional $8.5 million to upgrade facilities to reduce the amount of transfat produced during oil processing, while working closely with more than 100 additional customers in two dozen countries to reformulate new product solutions that meet their needs.
iTFAs are most often formed through the partial hydrogenation of vegetable oils (PHOs) but can also be created by high thermal treatment during edible oil refining. In 2018, the WHO called for the global elimination of iTFAs by 2023, noting that trans fats intake greater than 1 percent of total energy intake is associated with coronary heart disease events and mortality.
"We’re extremely proud that we’ve met our commitment and helped fulfill our purpose -- nourishing the world in a safe, responsible and sustainable way,” said Natasha Orlova, Cargill vice president for edible oils and managing director for North America. “Taking this industry-leading step, even in countries without current iTFA legislation, helps ensure consistency in their supply chain for larger food manufacturers, while offering Cargill’s breadth of innovation and experience to smaller manufacturers.”
To ensure compliance, Cargill has added iTFAs to its larger food safety and quality assurance program. This systems-based approach includes multiple layers of monitoring, compliance and auditing.
In its latest progress report, the WHO noted that policies limiting the use of iTFAs have only been implemented in 60 of the world’s countries, covering approximately 43% of the global population. This leaves the majority of the world’s consumers at risk for continued iTFA consumption. The report called on major suppliers of oils and fats to “follow the pioneering effort of Cargill to remove industrially produced TFA from the products that are sold to food manufacturers globally.”1
“We are the first and only global edible oil supplier to commit to and meet the WHO standards consistently and across the board for our full global portfolio, and while we are understandably proud of this milestone, the WHO report highlights that much work remains,” Orlova said. “We have proven it is not only feasible to meet the iTFA recommendations while being mindful of saturated fat levels, but it can also be done without discernably changing the taste or texture of consumers’ favorite foods. We call upon other industry players to follow our lead and remove iTFAs from all their products, too.”
Cargill has also taken steps to help advance industry-wide reformulation during the past two years, particularly in countries that did not have iTFA regulation at the time of the company’s commitment. Among its actions, in Pakistan, Cargill partnered with the Sustainable Development Policy Institute on a public awareness campaign. In Malaysia and Mexico, the company interacted with industry, academic and government stakeholders to raise awareness of WHO best practices, while sharing experiences and expertise in iTFA reformulation.
1 “Countdown to 2023: WHO Report on Global Trans Fat Elimination,” World Health Organization, 2022. Download at: https://www.who.int/publications/i/item/9789240067233
About Cargill
Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.
Our 160,000 team members innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 159 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131485973/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
